Interaction between PPARγ2 variants and gender on the modulation of body weight

Obesity

Volumn 16, Issue 6, 2008, Pages 1467-1470

  Morini, Eleonora ^a,b   Tassi, Vittorio ^c   Capponi, Daria ^a,b   Ludovico, Ornella ^c   Dallapiccola, Bruno ^a,b   Trischitta, Vincenzo ^a,b,c   Prudente, Sabrina ^a,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CSS Scientific Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HUMAN; ITALY; MALE; METABOLISM; MIDDLE AGED; SEXUAL DEVELOPMENT;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAPLOTYPES; HUMANS; INSULIN; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA; SEX CHARACTERISTICS;

EID: 44449120021     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.225     Document Type: Article

References (22)

1. WHO World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. No. 894. WHO Technical Series: World Health Organization, Geneva, Switzerland, 2000.
2. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet 2005;6:221-634.
3. Rosen ED, Spiegelman BM. Rosen. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-37734.
4. Beamer BA, Yen CJ, Andersen RE et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806-1808.
5. Meirhaeghe A, Fajas L, Helbecque N et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-199.
6. Valve R, Sivenius K, Miettinen R et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84:3708-3712.
7. Hamann A, Münzberg H, Buttron P et al. Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. Eur J Endocrinol 1999;141:90-92.
8. Swarbrick MM, Chapman CM, McQuillan BM et al. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001;144:277-282.
9. Mori Y, Kim-Motoyama H, Katakura T et al. Effect of the Pro12Ala variant of the human peroxisome proliferatoractivated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998;251:195-198.
10. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
11. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-2497.
12. Weiss LA, Pan L, Abney M, Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nat Genet 2006;38:218-222.
13. González Sánchez JL, Serrano Ríos M, Fernández Perez C, Laakso M, Martínez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor g-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002;147:495-501.
14. Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARG gene variant on obesity characteristics in Brazil. Braz J Med Biol Res 2007;40:927-932.
15. Kittles R, Perola M, Peltonen L et al. Dual origins of Finns revealed by Y chromosome haplotype variation. Am J Hum Genet 1998;62:1171-1179.
16. Klaman LD, Boss O, Peroni OD et al. Increased energy expenditure decreased adiposity and tissue-specific insulin sensitivity in protein tyrosine phosphatase 1B- deficient mice. Mol Cell Biol 2000;20:5479-5489.
17. Prudente S, Chandalia M, Morini E et al. The Q121/Q121 genotype of ENPP1/PC-1 is associated with lower BMI in non-diabetic whites. Obesity (Silver Spring) 2007;15:1-4.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
19. Baratta R, Di Paola R, Spampinato D et al. Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARgamma2 (P12A) polymorphisms. J Mol Med 2003;81:718-723.
20. Meirhaeghe A, Fajas L, Helbecque N et al. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435-440.
21. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-1169.
22. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434.